Search Results
Your search for early matches 10107 pages
Showing 2951 - 3000Repurposing Available Drugs for COVID-19: An Ongoing Initiative
As of this writing, no drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19, although several have received emergency use authorization and many others are being used off-label during the pandemic. In addition to searching for novel therapies, David...
ASCO Guideline Update Offers Four Standards of Care for Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
A recent ASCO guideline update, prompted by data from several phase III randomized controlled trials, summarizes the evidence supporting the best initial treatment options for the management of noncastrate advanced, recurrent, or metastatic prostate cancer. The hope is that the guideline will help...
ASCO and Friends of Cancer Research Recommend Expanding Patient Access to Cancer Clinical Trials by Further Broadening Eligibility Criteria
ASCO and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients.1 The joint recommendations are detailed in a series of articles...
Expert Point of View: Roy S. Herbst, MD, PhD, FACP, FASCO, and Shinichi Toyooka, MD
The ASCO Post reached out to Roy S. Herbst, MD, PhD, FACP, FASCO, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, New Haven, for his thoughts on the LCMC3 trial of neoadjuvant atezolizumab.1 Dr. Herbst led...
Neoadjuvant Atezolizumab in Lung Cancer: LCMC3 Trial Meets Primary Endpoint
Neoadjuvant treatment with single-agent atezolizumab in patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and a pathologic complete response rate of 7%, in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study.1 The findings were...
Caroline Dive, CBE, PhD, FBPhS, FMedSci, Honored With Mary J. Matthews Pathology/Translational Research Award
Caroline Dive, CBE, PhD, FBPhS, FMedSci, Director of the CRUK Manchester Institute Cancer Biomarker Centre, University of Manchester, has been recognized by the International Association for the Study of Lung Cancer (IASLC) with the Mary J. Matthews Pathology/Translational Research Award. The award ...
Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma
Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess Margaret...
Study Finds More Than Half of Cancer Survivors Have Underlying Medical Conditions Associated With Developing Severe COVID-19
A new study found that more than half (56.4%) of cancer survivors in the United States reported having additional underlying medical conditions associated with severe COVID-19 illness.1 The report, appearing in JNCI: The Journal of the National Cancer Institute, suggests that the prevalence of...
CONFIRM Trial Reports Improvement in Survival With Nivolumab in Relapsed Malignant Mesothelioma
For the first time, a treatment has been shown to improve overall survival in heavily pretreated patients with relapsed malignant mesothelioma. In the phase III CONFIRM trial, single-agent nivolumab led to a significant improvement in both overall and progression-free survival, according to...
Expert Point of View: Frank Keller, MD, and E. Anders Kolb, MD
Frank Keller, MD, a pediatric hematologist/oncologist with Children’s Healthcare of Atlanta–Egleston Hospital, and E. Anders Kolb, MD, Director of the Nemours Center for Cancer and Blood Disorders, Nemours Children’s Health System in Delaware, provided comments on the studies for The ASCO Post....
Studies Provide Guidance on the Use of Blinatumomab in Pediatric Acute Lymphoblastic Leukemia
Monotherapy with blinatumomab as consolidation therapy before allogeneic stem cell transplant appears to be the optimal treatment for children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (ALL), according to an international phase III trial that compared this approach...
Overcoming Gender Disparity in Evaluating Sexual Health Following a Cancer Diagnosis
The results from a recent study showcase the disturbing prevalence of sexual dysfunction as a treatment side effect of cancer and gender disparity in how the problem is addressed by physicians.1 The study, conducted by James Taylor, MD, MPH, Chief Resident in the Department of Radiation Oncology at ...
The Emerging Role of Exercise in Cancer Prevention and Treatment
The holistic benefits derived from exercise in preventing and ameliorating chronic health conditions such as cardiovascular disease and diabetes are well documented. However, less is known about the salutary effects exercise may have across the cancer setting, especially during treatment....
Continued Survival Benefit With Durvalumab Plus Chemotherapy vs Chemotherapy Alone in Extensive-Stage SCLC
As reported in The Lancet Oncology by Jonathan W. Goldman, MD, of the David Geffen School of Medicine at University of California Los Angeles, and colleagues, updated results from the phase III CASPIAN trial show maintained improvement in overall survival with first-line durvalumab plus...
New Global Breast Cancer Initiative Highlights Renewed Commitment to Improve Survival
A major new collaborative effort, the Global Breast Cancer Initiative, was introduced by the World Health Organization (WHO), with the objective of reducing global breast cancer mortality by 2.5% per year until 2040, thereby averting an estimated 2.5 million deaths. In recognition of International ...
Complete Mesocolic Excision vs D2 Dissection in Patients Undergoing Laparoscopic Colectomy for Right-Sided Colon Cancer
In an analysis of early safety outcomes in a Chinese phase III trial (RELARC) reported in The Lancet Oncology, Xu et al found similar surgical complication rates with complete mesocolic excision vs D2 dissection in patients undergoing laparoscopic colectomy for right-sided colon cancer. The...
Hossein Borghaei, DO, on Bispecific T-Cell–Engager Immune Therapy for Small Cell Lung Cancer
Hossein Borghaei, DO, of Fox Chase Cancer Center, discusses phase I results from a study of AMG 757, an experimental bispecific T-cell–engager (BiTE) immune therapy aimed at the DLL3 molecular target in patients with small cell lung cancer. At this early stage, results show clinical efficacy and...
Expert Point of View: John C. Krauss, MD
Invited discussant John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, said he was impressed by the “rapidity with which the NRG-GI002 trial accrued,” which was about 10 months.1 “Equally...
Mental Health Service Use Among Testicular Cancer Survivors
In a Canadian population-based cohort study reported in the Journal of Clinical Oncology, Raphael et al found that survivors of testicular cancer were more likely to use mental health services in both the short and long term following treatment compared with the general population. Study Details...
Study Finds Missing Annual Mammogram Increases Risk of Death From Breast Cancer
Regular mammography screening substantially reduces the risk of dying from breast cancer, according to a large study of over half a million women published by Stephen W. Duffy, MSc, and colleagues in the journal Radiology. Researchers said women who skipped even one scheduled mammography screening...
Study Examines Extrapleural Pneumonectomy After IMRT for Malignant Pleural Mesothelioma
In a Canadian single-center phase II feasibility study reported in The Lancet Oncology, Cho et al found that a treatment protocol (surgery for mesothelioma after radiotherapy, also known as SMART) consisting of hemithoracic intensity-modulated radiotherapy (IMRT) followed by extrapleural...
ASCO’s Road to Recovery Report Outlines Lessons Learned From the COVID-19 Pandemic to Improve Oncology Care
In 2020, ASCO established the Steering Group on Cancer Care Delivery and Research in a Post-Pandemic Environment to evaluate the changes made in oncology care delivery, clinical research, and regulatory oversight in response to the COVID-19 pandemic as well as to make recommendations on how to...
CLEAR Trial: Is Lenvatinib Plus Pembrolizumab the Best First-Line Immunotherapy Doublet in Metastatic Renal Cell Carcinoma?
At the 2021 Genitourinary Cancers Symposium, Motzer et al presented the clinical results of the CLEAR trial, adding a novel regimen, lenvatinib plus pembrolizu-mab, to the growing armamentarium of first-line treatments for patients with metastatic clear cell renal cell carcinoma (RCC). The...
Updates From Selected Clinical Trials in Breast Cancer
Each year, following the San Antonio Breast Cancer Symposium (SABCS), The ASCO Post asks Jame Abraham, MD, FACP, to offer his picks of the most important and most clinically relevant research presented at this meeting. The following are summaries of studies that caught Dr. Abraham’s attention from ...
The Impact of a Pandemic on Mentorship in Medicine
When advising the younger members of our medical community on career decisions, I always list “access to the best mentorship” as the most important priority. By the time we hit residency, we have all proven ourselves able to extract from a book or a journal the facts essential to the practice of...
New Report Reviews Methods for Reducing Waste, Improving Efficiency With Expensive Injectable Medications
Every year, significant amounts of drugs left over and unused from single-dose vials are discarded, but because of the way drugs are priced and paid for in the United States, the cost of the discarded amount cannot be recouped, according to a new congressionally mandated report from the National...
New Framework to Address Cancer Care Disparities in Medically Underserved Populations
A new article published in JCO Oncology Practice puts forth a framework to guide researchers, health-care leaders, advocates, community- and patient-focused service organizations, and policy leaders in their work to address and promote health equity in cancer care access and treatment outcomes.1...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
In Case You Missed It: Brief Highlights From ASH 2020
In case you missed these while attending the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, below is a sampler of highlights that were not included in our first round of meeting coverage. Many of these reports are on early-phase clinical trials of agents that may raise...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Kenya
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Kenya. The aim of this special feature is to highlight the global cancer burden for various countries of the...
SIMPLIFY Trials: JAK Inhibitor Yields Long-Term Survival Benefit and Transfusion Independence in Myelofibrosis
Treatment with the novel JAK inhibitor momelotinib led to long-term overall survival and sustained transfusion independence in patients with intermediate- or high-risk myelofibrosis, according to updates from the SIMPLIFY-1 and SIMPLIFY-2 trials presented at the 2020 American Society of Hematology...
I Let Science, Not Emotion, Dictate My Treatment
I had my first experience with cancer when I was just 3 or 4 years old and complained to my mother that my “tummy hurt.” I was diagnosed with Wilms tumor, the same cancer my 18-month-old brother died of before I was born. I remember being in the hospital for weeks at a time and being known by...
Crystal Denlinger, MD, FACP, Named Chief Scientific Officer for NCCN
The National Comprehensive Cancer Network© (NCCN) recently announced the appointment of Crystal S. Denlinger, MD, FACP, to the newly created role of Senior Vice President, Chief Scientific Officer. In this position, Dr. Denlinger will help to steer strategic direction for the nonprofit as well as...
IASLC Honors Pan-Chyr Yang, MD, PhD, for Contributions to Lung Cancer Prevention
Pan-Chyr Yang, MD, PhD, Chair Professor at the National Taiwan University Hospital and Academician of Academia Sinica, Taiwan, received the Joseph W. Cullen Prevention/Early Detection Award from the International Association for the Study of Lung Cancer (IASLC) at the virtual IASLC 2020 World...
Expert Point of View: Yun Fan, MD, and Deborah Doroshow, MD, PhD
Invited discussant of KEYNOTE-598,1Yun Fan, MD, Director of Thoracic Tumor Center at Zhejiang Cancer Hospital in Hangzhou, China, suggested that patients with non–small cell lung cancer (NSCLC) with low PD-L1 expression and those with high tumor mutational burden may, in fact, derive the most...
When to Start a Conversation With Patients About Subsequent Primary Cancers
Among patients who survive a primary cancer, concern about recurrence, especially metastatic disease, is extremely common; however, information about future risk for subsequent primary cancers is seldom communicated to these patients, leading to missed opportunities to prevent or detect subsequent...
KEYNOTE-598: No Improvement With Addition of Ipilimumab to Pembrolizumab in NSCLC
In the phase III KEYNOTE-598 study, the addition of ipilimumab to pembrolizumab increased toxicity without boosting efficacy as first-line therapy for metastatic non–small cell lung cancer (NSCLC) in patients with high expression of PD-L1. The findings were presented at the International...
John Bartlett, MD, Pioneer in Infectious Diseases Research and Treatment, Dies at 83
John Bartlett, MD, a visionary physician-scientist and pioneer in HIV/AIDS study and treatment who built the infectious diseases division at The Johns Hopkins, died on January 19, 2021, in New York. He was 83 years old. “Over his long and illustrious career, John Bartlett epitomized the best of...
Joseph V. Simone, MD, Visionary Pediatric Oncologist and ‘Quintessential Mentor,’ Dies at 85
When Joseph V. Simone, MD, was 6 years old, he had his first experience with the death of a child. His 9-month-old brother became sick with the croup and was taken to the nearby children’s hospital, where he died a few days later, leaving Dr. Simone and his family devastated. Caring for sick...
Oncology Community Mourns the Death of Chemotherapy Pioneer Emil J Freireich, MD, FASCO
Legendary oncologist Emil J Freireich, MD, FASCO, died from COVID-19 on February 1, 2021, at The University of Texas MD Anderson Cancer Center in Houston, where he had worked for 50 years. He was 93. During a career that spanned more than 6 decades, Dr. Freireich was relentless in pursuing cures...
The CARG-BC Score: Novel Tool for Predicting Chemotherapy Toxicity in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology, Allison Magnuson, DO, of the University of Rochester Medical Center & Wilmot Cancer Institute, and Mina S. Sedrak, MD, MS, of the City of Hope National Medical Center, along with colleagues, have developed a novel risk tool—the Cancer and Aging...
COVID-19 and Cancer: A Toxic Combination
COVID-19 has caused 475,000 deaths in America, disproportionately among communities of color, poverty, immigrants, and older age. It has exposed a variety of inequities within our health-care system. However, the patients at greatest risk of death from COVID-19 are those with cancer. While 1.8% of...
Genome-Edited Donor-Derived Anti-CD19 CAR T-Cell Therapy Is Active in B-Cell Acute Lymphoblastic Leukemia
Pooled results of two phase I studies, reported in The Lancet by Reuben Benjamin, MBBS, of the Department of Haematological Medicine, King’s College Hospital, London, and colleagues, indicate that the genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell product...
Novel Approaches in Chronic Lymphocytic Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic approaches in chronic lymphocytic leukemia (CLL). For full...
B-Cell and T-Cell Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin...
How the COVID-19 Pandemic Can Help Improve Cancer Research
The ripple effects of the coronavirus pandemic have been felt in every area of health care. In our medical specialty, oncology, clinical trials of new treatments were upended by COVID-19. In the early months of the pandemic, widespread interruptions in trial enrollment prevented some patients...
One-Third of Cancer Survivors Reported Worry About Health-Care Disruptions Early in the COVID-19 Pandemic
A new study published by Corinne Leach, MPH, MS, PhD, and colleagues in the Journal of Psychosocial Oncology reported that early in the COVID-19 pandemic in the United States, one-third of cancer survivors worried about treatment and cancer care disruptions. Using a mixed-methods approach,...
Expert Point of View: Meredith Regan, ScD, and Sara Hurvitz, MD
In the San Antonio meeting’s closing session, “View From the Trenches: What Will You Do Monday Morning?” Meredith Regan, ScD, and Sara Hurvitz, MD, offered their thoughts on the use of RSClin in the clinic, as described at the San Antonio Breast Cancer Symposium by Joseph Sparano, MD.1 Dr. Regan...
Prognostic Tool RSClin Introduced for Early Breast Cancer
Data from the TAILORx study and several National Surgical Adjuvant Breast and Bowel Project (NSABP) trials have been used to develop a new prognostic tool, RSClin, which aims to individualize the estimate of recurrence risk in early breast cancer and to more accurately predict the risk-reduction...
Can Weight Loss During Treatment and Follow-up Affect Breast Cancer Outcomes?
Research published by Martel et al in JNCCN—Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for patients with HER2-positive early breast cancer—and found a 5% weight loss in patients over 2 years was associated with worse outcomes. Weight gain over the same...
